7x Winner of the MMIT Patient Choice Award!

Give us a call 855.726.8479 | 412.246.9858

PANTHERx® Specialty Pharmacy is honored to announce our sponsorship of the Soft Bones International Scientific Meeting to promote education and advocacy for hypophosphatasia (HPP). This meeting will host the thought leaders and treatment experts in hypophosphatasia from across the world to promote research of this rare bone disease through awareness and fundraising efforts. The Inaugural Soft Bones International Scientific Meeting is being organized by the Soft Bones Foundation and will take place from June 8-10th in Rosemont, Illinois. PANTHERx® is the sole specialty pharmacy in the United States with the experience and focus to assist HPP patients in their treatment journeys.

About the Soft Bones Foundation

Started in 2009, the Soft Bones Foundation’s goal is to educate, empower, and connect patients living with hypophosphatasia (HPP), their families, and caregivers. Through research grants, public advocacy, and awareness efforts, the foundation seeks to improve the lives of those afflicted by HPP.

More information about the Soft Bones Foundation can be found at www.softbones.org.

About Hypophosphatasia (HPP)

Hypophosphatasia is a metabolic bone condition that affects the development of bones and teeth, softening them and making them more likely to fracture. HPP is caused by a faulty TNSALP or ALPL gene that can pass down through generations of family, but just because someone carries the gene does not guarantee that they exhibit any symptoms.

These defective genes can make it difficult for those with HPP to make an enzyme called alkaline phosphatase, whose absence can prevent calcium and phosphorus from binding together and depositing in bones. Without the calcium or phosphorus, bones can become soft, curved, and fragile. This can also make teeth become loose and fall out prematurely.

Symptoms of HPP can vary in degree from small abnormalities to life-threatening problems. It is classified as a rare disease, and it is estimated that severe forms of the disease occur in approximately one of every 100,000 live births.